 Jennifer Trujillo
Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 20 | 2022 | 1012 | 4.330 |
Why?
| | Diabetes Mellitus, Type 2 | 21 | 2022 | 2094 | 3.760 |
Why?
| | Education, Pharmacy | 11 | 2023 | 123 | 3.700 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 9 | 2022 | 72 | 2.820 |
Why?
| | Students, Pharmacy | 9 | 2019 | 98 | 2.680 |
Why?
| | Glucagon-Like Peptides | 5 | 2020 | 22 | 2.060 |
Why?
| | Glucagon-Like Peptide 1 | 6 | 2018 | 101 | 1.660 |
Why?
| | Peptides | 7 | 2018 | 848 | 1.560 |
Why?
| | Receptors, Glucagon | 3 | 2015 | 23 | 1.420 |
Why?
| | Insulin Glargine | 4 | 2022 | 73 | 1.350 |
Why?
| | Educational Measurement | 8 | 2019 | 243 | 1.230 |
Why?
| | Hypoglycemia | 6 | 2022 | 386 | 1.230 |
Why?
| | Insulin | 8 | 2022 | 2078 | 1.080 |
Why?
| | Curriculum | 8 | 2023 | 819 | 0.950 |
Why?
| | Blood Glucose | 9 | 2020 | 1826 | 0.910 |
Why?
| | Teaching | 2 | 2015 | 213 | 0.820 |
Why?
| | Liraglutide | 4 | 2016 | 27 | 0.780 |
Why?
| | Immunoglobulin Fc Fragments | 3 | 2020 | 35 | 0.770 |
Why?
| | Pharmacists | 3 | 2019 | 233 | 0.740 |
Why?
| | Anti-Obesity Agents | 3 | 2016 | 45 | 0.730 |
Why?
| | Glucagon | 1 | 2020 | 92 | 0.670 |
Why?
| | Metformin | 2 | 2020 | 276 | 0.650 |
Why?
| | Recombinant Fusion Proteins | 3 | 2020 | 616 | 0.640 |
Why?
| | Emergency Treatment | 1 | 2020 | 113 | 0.630 |
Why?
| | Hyperglycemia | 2 | 2014 | 291 | 0.610 |
Why?
| | Medication Therapy Management | 1 | 2019 | 67 | 0.600 |
Why?
| | Patient Education as Topic | 4 | 2018 | 680 | 0.590 |
Why?
| | Societies, Pharmaceutical | 2 | 2016 | 27 | 0.580 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 182 | 0.540 |
Why?
| | Weight Loss | 6 | 2022 | 642 | 0.480 |
Why?
| | Education, Pharmacy, Graduate | 2 | 2017 | 21 | 0.470 |
Why?
| | Drugs, Investigational | 1 | 2014 | 30 | 0.470 |
Why?
| | Problem-Based Learning | 2 | 2017 | 78 | 0.470 |
Why?
| | Humans | 38 | 2023 | 114654 | 0.450 |
Why?
| | Drug Combinations | 4 | 2018 | 287 | 0.450 |
Why?
| | Body Weight | 4 | 2020 | 870 | 0.420 |
Why?
| | Health Literacy | 1 | 2015 | 164 | 0.410 |
Why?
| | Peer Review | 1 | 2012 | 43 | 0.390 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2022 | 82 | 0.390 |
Why?
| | Drug Administration Schedule | 3 | 2020 | 718 | 0.390 |
Why?
| | Patient-Centered Care | 1 | 2016 | 473 | 0.390 |
Why?
| | Learning | 1 | 2015 | 350 | 0.370 |
Why?
| | Interpersonal Relations | 1 | 2014 | 341 | 0.370 |
Why?
| | Faculty, Medical | 1 | 2012 | 228 | 0.330 |
Why?
| | Pancreatitis | 1 | 2010 | 107 | 0.320 |
Why?
| | Diet Records | 1 | 2009 | 76 | 0.320 |
Why?
| | Cardiovascular Diseases | 2 | 2017 | 1727 | 0.310 |
Why?
| | Cultural Competency | 1 | 2009 | 72 | 0.310 |
Why?
| | Attitude of Health Personnel | 3 | 2015 | 975 | 0.300 |
Why?
| | Communication | 4 | 2016 | 744 | 0.300 |
Why?
| | Drug Interactions | 1 | 2009 | 338 | 0.300 |
Why?
| | Empathy | 1 | 2009 | 139 | 0.290 |
Why?
| | Peer Group | 1 | 2008 | 201 | 0.280 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 900 | 0.280 |
Why?
| | Clinical Trials as Topic | 3 | 2020 | 931 | 0.270 |
Why?
| | Schools, Pharmacy | 2 | 2017 | 48 | 0.270 |
Why?
| | Obesity | 2 | 2016 | 2508 | 0.270 |
Why?
| | Clinical Protocols | 1 | 2008 | 233 | 0.270 |
Why?
| | Program Evaluation | 3 | 2017 | 822 | 0.270 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 951 | 0.240 |
Why?
| | Spironolactone | 1 | 2004 | 28 | 0.230 |
Why?
| | Drug Utilization Review | 1 | 2004 | 57 | 0.220 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2004 | 38 | 0.220 |
Why?
| | Family Practice | 1 | 2008 | 427 | 0.220 |
Why?
| | Venoms | 2 | 2015 | 30 | 0.220 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2022 | 14 | 0.210 |
Why?
| | Injections, Subcutaneous | 2 | 2014 | 134 | 0.190 |
Why?
| | Patient Compliance | 1 | 2004 | 525 | 0.170 |
Why?
| | Administration, Intranasal | 1 | 2020 | 75 | 0.170 |
Why?
| | Professional Role | 2 | 2019 | 149 | 0.170 |
Why?
| | Delayed-Action Preparations | 1 | 2020 | 159 | 0.170 |
Why?
| | Nausea | 1 | 2020 | 101 | 0.170 |
Why?
| | Internship and Residency | 1 | 2008 | 926 | 0.150 |
Why?
| | Cardiovascular System | 1 | 2020 | 125 | 0.150 |
Why?
| | Treatment Outcome | 3 | 2020 | 9087 | 0.150 |
Why?
| | Postprandial Period | 1 | 2018 | 87 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2016 | 1183 | 0.150 |
Why?
| | Insulin, Long-Acting | 1 | 2017 | 52 | 0.140 |
Why?
| | Administration, Oral | 1 | 2020 | 728 | 0.140 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2017 | 3 | 0.140 |
Why?
| | Perception | 1 | 2019 | 311 | 0.140 |
Why?
| | Canagliflozin | 1 | 2017 | 8 | 0.140 |
Why?
| | Glucosides | 1 | 2017 | 36 | 0.140 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 60 | 0.130 |
Why?
| | Surveys and Questionnaires | 3 | 2019 | 4622 | 0.130 |
Why?
| | Professional Practice | 1 | 2016 | 62 | 0.130 |
Why?
| | Self-Management | 1 | 2018 | 126 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1214 | 0.130 |
Why?
| | Self Care | 1 | 2018 | 349 | 0.120 |
Why?
| | Counseling | 1 | 2018 | 342 | 0.120 |
Why?
| | Drug Approval | 1 | 2015 | 78 | 0.120 |
Why?
| | Sitagliptin Phosphate | 1 | 2015 | 30 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 172 | 0.120 |
Why?
| | Pyrazines | 1 | 2015 | 71 | 0.120 |
Why?
| | Adult | 6 | 2022 | 30542 | 0.110 |
Why?
| | Disease Management | 1 | 2018 | 560 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2015 | 142 | 0.110 |
Why?
| | Pilot Projects | 2 | 2008 | 1373 | 0.110 |
Why?
| | Triazoles | 1 | 2015 | 131 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2022 | 12544 | 0.110 |
Why?
| | Comprehension | 1 | 2014 | 156 | 0.100 |
Why?
| | Community Pharmacy Services | 1 | 2012 | 42 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2312 | 0.100 |
Why?
| | Educational Status | 1 | 2014 | 412 | 0.100 |
Why?
| | Algorithms | 1 | 2019 | 1467 | 0.100 |
Why?
| | Male | 7 | 2022 | 55579 | 0.100 |
Why?
| | Pharmacy Service, Hospital | 1 | 2012 | 83 | 0.100 |
Why?
| | Feedback | 1 | 2012 | 144 | 0.100 |
Why?
| | United States | 3 | 2016 | 12179 | 0.090 |
Why?
| | Heart Failure | 1 | 2004 | 1945 | 0.090 |
Why?
| | Female | 7 | 2022 | 59488 | 0.090 |
Why?
| | Comorbidity | 1 | 2015 | 1448 | 0.090 |
Why?
| | Health Care Costs | 3 | 2022 | 381 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2012 | 253 | 0.090 |
Why?
| | Clinical Competence | 1 | 2016 | 893 | 0.090 |
Why?
| | Patient Safety | 1 | 2012 | 277 | 0.080 |
Why?
| | Data Collection | 1 | 2012 | 620 | 0.080 |
Why?
| | Observer Variation | 1 | 2008 | 295 | 0.070 |
Why?
| | Boston | 1 | 2008 | 75 | 0.070 |
Why?
| | Professional-Patient Relations | 1 | 2009 | 141 | 0.070 |
Why?
| | Advisory Committees | 1 | 2008 | 208 | 0.070 |
Why?
| | Acute Disease | 1 | 2010 | 910 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2008 | 311 | 0.060 |
Why?
| | Aged | 4 | 2022 | 19068 | 0.060 |
Why?
| | Concurrent Review | 1 | 2004 | 2 | 0.060 |
Why?
| | Massachusetts | 1 | 2004 | 134 | 0.060 |
Why?
| | Guideline Adherence | 1 | 2008 | 490 | 0.060 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 103 | 0.060 |
Why?
| | Hospitals, Urban | 1 | 2004 | 127 | 0.050 |
Why?
| | Patient Care Team | 1 | 2008 | 517 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2008 | 2762 | 0.050 |
Why?
| | Hospitalization | 1 | 2008 | 1750 | 0.040 |
Why?
| | Middle Aged | 3 | 2012 | 26732 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3252 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2012 | 6345 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2019 | 1226 | 0.030 |
Why?
| | Prospective Studies | 1 | 2008 | 6217 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2004 | 2537 | 0.030 |
Why?
| | Phentermine | 1 | 2016 | 8 | 0.030 |
Why?
| | Bupropion | 1 | 2016 | 39 | 0.030 |
Why?
| | Benzazepines | 1 | 2016 | 37 | 0.030 |
Why?
| | Motivation | 1 | 2019 | 494 | 0.030 |
Why?
| | Fructose | 1 | 2016 | 100 | 0.030 |
Why?
| | Naltrexone | 1 | 2016 | 83 | 0.030 |
Why?
| | Cough | 1 | 2014 | 107 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 475 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2014 | 641 | 0.030 |
Why?
| | Pharmacology, Clinical | 1 | 2012 | 8 | 0.030 |
Why?
| | Medication Reconciliation | 1 | 2012 | 25 | 0.030 |
Why?
| | Health Personnel | 1 | 2017 | 574 | 0.020 |
Why?
| | Medical Informatics | 1 | 2012 | 90 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 184 | 0.020 |
Why?
| | Creatinine | 1 | 2012 | 425 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4099 | 0.020 |
Why?
| | Quality Improvement | 1 | 2012 | 950 | 0.020 |
Why?
| | Interprofessional Relations | 1 | 2006 | 249 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 4895 | 0.010 |
Why?
|
|
Trujillo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|